Tech Center 1600 • Art Units: 1622 1626 1628 1642
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18281162 | PROCESS FOR PREPARING POLYCYCLIC ODORANTS | Final Rejection | SYMRISE AG |
| 17906138 | TREATMENT OF EPILEPSY | Non-Final OA | Katholieke Universiteit Leuven |
| 18546633 | Treatment of Hypertension-Related and Vascular Diseases | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18455206 | SUBSTITUTED HETEROCYCLES FOR TREATING CANCER | Non-Final OA | Northwestern University |
| 17783455 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY A PHYTOPATHOGENIC MICROORGANISM OF THE GENUS MACROPHOMINA SPP. | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18550234 | KRAS G12D INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18833767 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18260293 | COMPOSITIONS COMPRISING ANATABINE AND USES THEREOF | Non-Final OA | Philip Morris Products S.A. |
| 18002403 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Non-Final OA | Philip Morris Products S.A. |
| 18248663 | USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER (S)-4-((1-BENZYLPYRROLIDIN-3-YL)(METHYL)AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL)BENZENESULFONAMIDE, TOGETHER WITH STRONG INDUCERS OF CYTOCHROME P450 3A4, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAVI.6 ACTIVITY | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18570520 | PROTEASE INHIBITORS AND METHODS OF USE | Non-Final OA | The Cleveland Clinic Foundation |
| 18033724 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | MERCK PATENT GMBH |
| 18260744 | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use | Non-Final OA | YALE UNIVERSITY |
| 18564778 | METHODS OF TREATING BREAST CANCER | Non-Final OA | ASTRAZENECA AB |
| 18010695 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 17912272 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 19025976 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | Non-Final OA | Iambic Therapeutics, Inc. |
| 18357320 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Non-Final OA | Iambic Therapeutics, Inc. |
| 18178192 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18030390 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18295484 | EPIGENETIC MODIFIERS TO TREAT RETINAL DEGENERATIONS | Non-Final OA | The Penn State Research Foundation |
| 18227103 | NOVEL COMPOUNDS | Non-Final OA | AC Immune SA |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Non-Final OA | Gilead Sciences, Inc. |
| 18248068 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18030529 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18030527 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18030530 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18248071 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18030537 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 17916904 | TOPICAL USE OF ERLOTINIB FOR TREATING KERATODERMAS IN CHILDREN | Final Rejection | UNIVERSITE PARIS-SACLAY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy